Kennedy faces sharp rebuke from House Democrats over vaccine policy

25 June 2025

Health and Human Services Secretary Robert F Kennedy Jr came under heavy scrutiny from Democratic lawmakers during a heated budget hearing on Capitol Hill, as concerns mounted over his handling of vaccine policy, sweeping agency cuts, and what some members described as a disregard for transparency and scientific integrity.

Appearing before the House Energy and Commerce Subcommittee, Mr Kennedy was grilled on the Trump administration’s proposed fiscal 2026 health budget. The session quickly turned into a political reckoning, with lawmakers pressing him on what they characterized as misleading testimony during his Senate confirmation, controversial reversals in public health guidance, and a series of administrative decisions that have drawn backlash from medical and scientific communities.

One of the most contentious moments came when Mr Kennedy was forced to retract a claim that Representative Frank Pallone’s support for vaccine policy was linked to pharmaceutical contributions. Mr Kennedy’s remark, which accused the New Jersey Democrat of receiving $2 million from drugmakers, prompted a formal objection and a warning from the Republican chair.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical